MinorMineral supplements. Macrominerals×Muscarinic receptor antagonist for overactive bladder
Updated · Methodology
Mechanism
In the liver, CYP2D6 converts tolterodine into its active 5-hydroxymethyl metabolite. In people without CYP2D6 activity, CYP3A4 metabolises it instead. The metabolites are excreted mainly in urine (Detrusitol Neo SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Detrol label, US Food and Drug Administration, FDA). Magnesium from oral salts is absorbed slowly in the small intestine, binds weakly to plasma proteins and is excreted mainly in urine. Oral magnesium lactate has a bioavailability of about 35% (Magnesioboi SmPC, AEMPS). Magnesium salts reduce the absorption of tetracyclines, quinolones and bisphosphonates by forming complexes, and weaken azole antifungals by lowering stomach acidity (magnesium salt SmPCs, AEMPS). Tolterodine is not in these lists, and the tolterodine documents mention neither magnesium nor antacids (AEMPS and FDA documents for both).
Symptoms
The documents describe no symptoms linked to this combination. The most common adverse effect of tolterodine is dry mouth, and indigestion, constipation, abdominal pain, dry eyes, dizziness and drowsiness are also common (Detrusitol Neo SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Magnesium salts most often cause watery diarrhoea, especially at high doses, and vomiting. In severe renal impairment, blood magnesium can rise and cause drowsiness, double vision, dizziness, muscle weakness and low blood pressure (Magnesioboi SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of tolterodine and magnesium need no change. No document names the pair. The magnesium salt SmPCs do not list tolterodine among drugs to take at a different time from magnesium, and the tolterodine documents mention neither magnesium nor antacids (magnesium salt and tolterodine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; Detrol label, US Food and Drug Administration, FDA). In severe renal impairment (glomerular filtration rate 30 mL/min or less), the recommended tolterodine dose is 2 mg once daily (Detrusitol Neo SmPC, AEMPS). Magnesium salts are contraindicated in severe renal impairment because of the risk of hypermagnesaemia (Magnesioboi SmPC, AEMPS). Magnesium salts are also contraindicated in heart block, ischaemic heart disease and arrhythmias (Magnesioboi SmPC, AEMPS). Use tolterodine with caution in people with risk factors for QT prolongation, including low potassium, magnesium or calcium, bradycardia and significant heart disease (Detrusitol Neo SmPC, AEMPS). With prolonged magnesium use, check blood magnesium and calcium (Magnesioboi SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Lactato de magnesio, Magnesioboi 48,62 mg comprimidos (nº registro 54347), sección 4.5 (2025)– AEMPS, CIMA, nº registro 54347 (Magnesioboi 48,62 mg comprimidos, Laboratorios Cinfa), revisión 07/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8 y 5.2
- AEMPS: Ficha técnica: Pidolato de magnesio, Actimag 400 mg/ml solución oral (nº registro 56322), sección 4.5 (2025)– AEMPS, CIMA, nº registro 56322 (Actimag 400 mg/ml solución oral, Faes Farma), revisión 01/2025, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Tolterodina, Detrusitol Neo 4 mg cápsulas duras de liberación prolongada (nº registro 64245), sección 4.5 (2025)– AEMPS, CIMA, nº registro 64245 (Detrusitol Neo 4 mg cápsulas duras de liberación prolongada, Farmasierra), revisión 01/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8 y 5.2
- FDA: Detrol (tolterodine tartrate) prescribing information (2023)– FDA, DailyMed setid 41eb00d2-64e3-4ec9-8732-4bfc81b04180 (Viatris Specialty), revised 02/2023 (version 5), CLINICAL PHARMACOLOGY (Drug-Drug Interactions), CONTRAINDICATIONS, PRECAUTIONS (Drug Interactions)